INVENTIVA (EPA:IVA) | Finanzwire

Basculer en Français

11018	Companies
241417	Keywords
169936	Articles
129971	Press releases

Home
Companies
INVENTIVA

PRESS RELEASE

published on 02/10/2025 at 22:00, 1 year 7 months ago

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Inventiva reports preliminary 2024 fiscal year financial results and business update, with €9.2 million revenues and €96.6 million cash as of December 31, 2024. Focused on lanifibranor development

Revenues Financial Results 2024 Fiscal Year Inventiva Lanifibranor
BRIEF

published on 01/24/2025 at 22:05, 1 year 7 months ago

Half-yearly report on Inventiva's liquidity contract with Kepler Cheuvreux

Liquidity Contract Kepler Cheuvreux Biopharmaceutical Stock Market Transactions Inventiva
PRESS RELEASE

published on 01/24/2025 at 22:00, 1 year 7 months ago

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Inventiva announces half-year liquidity contract review with Kepler Cheuvreux. Cash and shares available in the liquidity account disclosed. Company focuses on developing oral small molecule therapies for MASH and unmet medical needs

Liquidity Contract Kepler Cheuvreux Clinical-Stage Biopharmaceutical Inventiva MASH
BRIEF

published on 01/22/2025 at 22:05, 1 year 7 months ago

Inventiva's LEGEND Trial Results to be Presented at EASL SLD Summit 2025

Lanifibranor Empagliflozin LEGEND Trial MASH Treatment EASL Summit 2025
PRESS RELEASE

published on 01/22/2025 at 22:00, 1 year 7 months ago

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Inventiva announces selection of LEGEND trial results evaluating lanifibranor and empagliflozin for oral presentation at EASL SLD Summit 2025, showing positive outcomes in MASH patients with T2D

Inventiva MASH Lanifibranor Empagliflozin LEGEND Trial
BRIEF

published on 12/17/2024 at 22:05, 1 year 9 months ago

Inventiva to present at the JP Morgan Healthcare Conference

Investors Inventiva NASH Lanifibranor JP Morgan Healthcare
PRESS RELEASE

published on 12/17/2024 at 22:00, 1 year 9 months ago

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference with CEO Frédéric Cren providing a corporate overview and engaging in investor meetings

Biopharmaceutical Inventiva J.P. Morgan Healthcare Conference Frédéric Cren Metabolic Dysfunction
BRIEF

published on 12/12/2024 at 22:05, 1 year 9 months ago

Inventiva Announces Shareholders’ Meeting Vote Results

Voting Results Shareholders' Meeting Biopharmaceutical Resolutions Inventiva
PRESS RELEASE

published on 12/12/2024 at 22:00, 1 year 9 months ago

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
Inventiva announces voting results of Combined Shareholders' General Meeting on December 11, 2024. All resolutions were adopted except the 59th resolution

Voting Results Shareholders' Meeting Clinical-Stage Biopharmaceutical Inventiva NASH
BRIEF

published on 11/21/2024 at 22:05, 1 year 9 months ago

Inventiva's Financial Overview for Q3 2024

Financial Results Cash Position Equity Raise Royalty Certificates R&D Expenses

Accesswire

Published on 09/18/2026 at 00:55, 3 hours 1 minute ago

Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 00:25, 3 hours 31 minutes ago

CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 5 hours 41 minutes ago

Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/17/2026 at 22:15, 5 hours 41 minutes ago

Vanta Attends 2026 All-In Summit in Los Angeles, a Leading Gathering of Business, Investment and Industry Leaders
Published on 09/17/2026 at 22:05, 5 hours 51 minutes ago

Loop Industries Forms Strategic Alternatives Committee to Maximize Shareholder Value

View all ACCESSWIRE

EQS Group

Published on 09/17/2026 at 19:00, 8 hours 56 minutes ago

Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 18:58, 8 hours 58 minutes ago

EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Published on 09/17/2026 at 18:25, 9 hours 31 minutes ago

Magentic raises $18M to build the AI workforce for the physical world
Published on 09/17/2026 at 18:10, 9 hours 46 minutes ago

A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Published on 09/17/2026 at 17:46, 10 hours 10 minutes ago

RBI categorically denies the allegations of short-seller report

Les Echos

Published on 09/17/2026 at 17:40, 10 hours 16 minutes ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 1 day 7 hours ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 1 day 10 hours ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 1 day 10 hours ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 20 hours ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification

View all LES ECHOS COMFI WIRE